1. In patients with chronic limb-threatening ischemia, large adverse limb events and mortality were importantly little with surgical revascularization than with endovascular treatment.
2. No important differences were seen betwixt groups successful patients without an capable saphenous vein conduit.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Chronic limb-threatening ischemia is the astir terrible signifier of peripheral artery disease, characterized by ischemic ft symptom astatine rest, ischemic ulcerations, oregon gangrene. Timely revascularization with surgical bypass oregon endovascular therapy is indispensable to forestall limb amputation. There is simply a paucity of information comparing these revascularization approaches. This randomized objective proceedings compared surgical bypass and endovascular therapy successful patients with chronic limb-threatening ischemia. Patients were further classified arsenic those with a azygous conception of the large saphenous vein (cohort one) oregon those who required an alternate bypass conduit (cohort two). For cohort one, large adverse limb events oregon decease from immoderate origin occurred importantly much successful the endovascular radical compared to the surgical group. There were nary important differences successful the incidence of large adverse cardiovascular events. For cohort two, the incidence of large adverse limb events, mortality, oregon cardiovascular events was not importantly antithetic betwixt groups. As a limitation, determination was procedural heterogeneity wrong each proceedings group, including femoral-popliteal, femoral-tibial, oregon popliteal-tibial bypass for surgical attraction and superficial femoral artery, popliteal artery, and tibial artery for endovascular treatment. Further, the proceedings whitethorn not beryllium statistically powered to observe a comparative quality of 25% successful the superior outcome, arsenic the planned fig of patients enrolled successful the proceedings was not met.
Click to work the survey successful NEJM
In-Depth [randomized controlled trial]: This randomized objective proceedings compared surgical bypass and endovascular therapy successful patients with chronic limb-threatening ischemia. Patients were classified arsenic those with a azygous conception of the large saphenous vein (cohort one; n=1,434) oregon those who required an alternate bypass conduit (cohort two; n=396) and past randomized successful a one-to-one ratio into surgical and endovascular treatments. Cohorts 1 and 2 were followed for a median of 2.7 and 1.6 years, respectively. The superior result was a composite of large adverse limb events (above-ankle amputation oregon large reintervention) oregon decease from immoderate cause. The secondary outcomes were the occurrence of a large adverse limb lawsuit overall, decease wrong 30 days post-operation, insignificant reinterventions, oregon a large adverse cardiovascular event. For cohort one, the superior result occurred successful 42.6% and 57.4% of the surgical and endovascular groups, respectively (Hazard Ratio [HR], 0.68; 95% Confidence Interval [CI], 0.59 to 0.79; p<0.001). For the idiosyncratic superior outcomes successful cohort one, the incidence of large reinterventions (HR, 0.35; 95% CI, 0.27 to 0.47) and above-ankle amputations (HR, 0.73; 95% CI, 0.54 to 0.98) were importantly higher successful the endovascular group. The incidence of decease was not importantly antithetic betwixt groups. Recurrence of chronic limb-threatening ischemia was little successful the surgical radical compared to the endovascular radical successful cohort 1 (incidence complaint ratio, 0.82; 95% CI, 0.70 to 0.95). There were nary important differences successful secondary outcomes. For cohort two, superior and secondary outcomes were not importantly antithetic betwixt groups. This survey suggests that archetypal bypass country whitethorn effect successful amended objective outcomes for chronic limb-threatening ischemia patients with an capable azygous conception of large saphenous vein for the conduit.
Image: PD
©2022 2 Minute Medicine, Inc. All rights reserved. No works whitethorn beryllium reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire astir licensing here. No nonfiction should beryllium construed arsenic aesculapian proposal and is not intended arsenic specified by the authors oregon by 2 Minute Medicine, Inc.
English (US)